| Basics |
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
|
| IPO Date: |
July 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$8.34B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.46 | 3.24%
|
| Avg Daily Range (30 D): |
$1.88 | 4.10%
|
| Avg Daily Range (90 D): |
$1.13 | 3.29%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.8M |
| Avg Daily Volume (30 D): |
2.11M |
| Avg Daily Volume (90 D): |
2.03M |
| Trade Size |
| Avg Trade Size (Sh.): |
118 |
| Avg Trade Size (Sh.) (30 D): |
68 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Inst.Trades: |
5,233 |
| Avg Inst. Trade: |
$3.27M |
| Avg Inst. Trade (30 D): |
$5.78M |
| Avg Inst. Trade (90 D): |
$4.55M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.57M |
| Avg Closing Trade (30 D): |
$10.83M |
| Avg Closing Trade (90 D): |
$9.31M |
| Avg Closing Volume: |
182.84K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-.01
|
$-.18
|
$-.01
|
|
Diluted EPS
|
$-.01
|
$-.18
|
$-.01
|
|
Revenue
|
$ 829.45M
|
$ 256.47M
|
$ 829.45M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 30.11M
|
$ 16.12M
|
$ 30.11M
|
|
Operating Income / Loss
|
$ 98.35M
|
$ 44.11M
|
$ 98.35M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 123.86M
|
$ 96.76M
|
$ 123.86M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Nov 17, 2011:
1:10
|
|
Jan 15, 2004:
1:65
|
|
|
|
